211 related articles for article (PubMed ID: 25726524)
1. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
Rincón R; Cristóbal I; Zazo S; Arpí O; Menéndez S; Manso R; Lluch A; Eroles P; Rovira A; Albanell J; García-Foncillas J; Madoz-Gúrpide J; Rojo F
Oncotarget; 2015 Feb; 6(6):4299-314. PubMed ID: 25726524
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.
Chen PM; Chu PY; Tung SL; Liu CY; Tsai YF; Lin YS; Wang WL; Wang YL; Lien PJ; Chao TC; Tseng LM
Hum Pathol; 2017 Aug; 66():93-100. PubMed ID: 28603063
[TBL] [Abstract][Full Text] [Related]
3. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.
Cristóbal I; Rincón R; Manso R; Caramés C; Zazo S; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Clin Cancer Res; 2015 Jan; 21(2):347-56. PubMed ID: 25388166
[TBL] [Abstract][Full Text] [Related]
4. PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.
Velmurugan BK; Lee CH; Chiang SL; Hua CH; Chen MC; Lin SH; Yeh KT; Ko YC
J Cell Physiol; 2018 Feb; 233(2):1300-1311. PubMed ID: 28516459
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
[TBL] [Abstract][Full Text] [Related]
6. Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
Cristóbal I; González-Alonso P; Daoud L; Solano E; Torrejón B; Manso R; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mar Drugs; 2015 May; 13(6):3276-86. PubMed ID: 26023836
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
8. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
Cristóbal I; Garcia-Orti L; Cirauqui C; Alonso MM; Calasanz MJ; Odero MD
Leukemia; 2011 Apr; 25(4):606-14. PubMed ID: 21233840
[TBL] [Abstract][Full Text] [Related]
9. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
10. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.
Chung A; Choi M; Han BC; Bose S; Zhang X; Medina-Kauwe L; Sims J; Murali R; Taguiam M; Varda M; Schiff R; Giuliano A; Cui X
Clin Breast Cancer; 2015 Dec; 15(6):448-457.e2. PubMed ID: 26248960
[TBL] [Abstract][Full Text] [Related]
11. EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo.
Jin Y; Zhang W; Wang H; Zhang Z; Chu C; Liu X; Zou Q
Oncol Rep; 2016 Feb; 35(2):771-8. PubMed ID: 26718028
[TBL] [Abstract][Full Text] [Related]
12. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation.
Cristóbal I; Rincón R; Manso R; Madoz-Gúrpide J; Caramés C; del Puerto-Nevado L; Rojo F; García-Foncillas J
Biochim Biophys Acta; 2014 Sep; 1842(9):1823-9. PubMed ID: 24997451
[TBL] [Abstract][Full Text] [Related]
13. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
[TBL] [Abstract][Full Text] [Related]
14. The far-upstream element-binding protein 2 is correlated with proliferation and doxorubicin resistance in human breast cancer cell lines.
Wang YY; Gu XL; Wang C; Wang H; Ni QC; Zhang CH; Yu XF; Yang LY; He ZX; Mao GX; Yang SY
Tumour Biol; 2016 Jul; 37(7):9755-69. PubMed ID: 26810065
[TBL] [Abstract][Full Text] [Related]
15. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F; González-Navarrete I; Bragado R; Dalmases A; Menéndez S; Cortes-Sempere M; Suárez C; Oliva C; Servitja S; Rodriguez-Fanjul V; Sánchez-Pérez I; Campas C; Corominas JM; Tusquets I; Bellosillo B; Serrano S; Perona R; Rovira A; Albanell J
Clin Cancer Res; 2009 May; 15(10):3530-9. PubMed ID: 19417026
[TBL] [Abstract][Full Text] [Related]
16. CIP2A silencing alleviates doxorubicin resistance in MCF7/ADR cells through activating PP2A and autophagy.
Zhu Z; Wei Z
Clin Transl Oncol; 2021 Aug; 23(8):1542-1548. PubMed ID: 33948919
[TBL] [Abstract][Full Text] [Related]
17. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Kim MO; Choe MH; Yoon YN; Ahn J; Yoo M; Jung KY; An S; Hwang SG; Oh JS; Kim JS
Biochem Pharmacol; 2017 Nov; 144():78-89. PubMed ID: 28813646
[TBL] [Abstract][Full Text] [Related]
18. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
Jansen MP; Ruigrok-Ritstier K; Dorssers LC; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Helleman J; Sleijfer S; Klijn JG; Foekens JA; Berns EM
Breast Cancer Res Treat; 2009 Jul; 116(2):263-71. PubMed ID: 18629630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
